Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.

von Bubnoff, N; Peschel, C; Duyster, J

von Bubnoff, N; Peschel, C; Duyster, J.

Affiliation

von Bubnoff N; 1Laboratory of Leukemogenesis, Department of Internal Medicine III, Technical University of Munich, Germany.

Leukemia ; 17(5): 829-38, 2003 May.

Article in En | MEDLINE | ID: mdl-12750693

Subject(s)

Antineoplastic Agents/therapeutic use; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl/antagonists & inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Piperazines/therapeutic use; Pyrimidines/therapeutic use; Benzamides; Fusion Proteins, bcr-abl/genetics; Humans; Imatinib Mesylate; Protein-Tyrosine Kinases/antagonists & inhibitors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Drug Resistance, Neoplasm / Antineoplastic Agents Limits: Humans Language: En Journal: Leukemia Year: 2003 Document type: Article

Search on Google

XML

PubMed Links